CDT Equity Inc. (NASDAQ: CDT) Stock Competitors & Peer Comparison
See CDT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CDT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CDT | $0.40 | -9.66% | 181.9K | N/A | -$157.83 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CDT vs VRTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 28.30. In terms of profitability, CDT's ROE is +0.09%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, CDT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CDT vs REGN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 20.94. In terms of profitability, CDT's ROE is +0.09%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CDT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
CDT vs MRNA Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MRNA has a market cap of 90.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MRNA trades at $223.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -27.41. In terms of profitability, CDT's ROE is +0.09%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, CDT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
CDT vs VRNA Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CDT's ROE is +0.09%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, CDT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for CDT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CDT vs ARGX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 34.62. In terms of profitability, CDT's ROE is +0.09%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, CDT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
CDT vs ONC Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ONC's P/E ratio is 73.33. In terms of profitability, CDT's ROE is +0.09%, compared to ONC's ROE of +0.18%. Regarding short-term risk, CDT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
CDT vs SGEN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CDT's ROE is +0.09%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CDT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CDT vs RVMD Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -19.53. In terms of profitability, CDT's ROE is +0.09%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, CDT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CDT vs RVMDW Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, CDT's ROE is +0.09%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, CDT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
CDT vs GMAB Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 38.71. In terms of profitability, CDT's ROE is +0.09%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, CDT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for CDT.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CDT vs ROIV Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -37.61. In terms of profitability, CDT's ROE is +0.09%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, CDT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
CDT vs INSM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -42.96. In terms of profitability, CDT's ROE is +0.09%, compared to INSM's ROE of -0.83%. Regarding short-term risk, CDT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CDT vs UTHR Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 21.15. In terms of profitability, CDT's ROE is +0.09%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CDT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for CDT.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
CDT vs INCY Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 16.26. In terms of profitability, CDT's ROE is +0.09%, compared to INCY's ROE of +0.07%. Regarding short-term risk, CDT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for CDT.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CDT vs ALNY Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 8.34. In terms of profitability, CDT's ROE is +0.09%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, CDT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
CDT vs BNTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -11.10. In terms of profitability, CDT's ROE is +0.09%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, CDT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CDT vs BGNE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CDT's ROE is +0.09%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, CDT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CDT vs DNA-WT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CDT's ROE is +0.09%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CDT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CDT vs ASND Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -113.80. In terms of profitability, CDT's ROE is +0.09%, compared to ASND's ROE of +1.08%. Regarding short-term risk, CDT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CDT vs EXEL Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 19.71. In terms of profitability, CDT's ROE is +0.09%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, CDT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for CDT.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CDT vs NBIX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 24.19. In terms of profitability, CDT's ROE is +0.09%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, CDT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CDT vs JAZZ Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, CDT's ROE is +0.09%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, CDT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for CDT.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CDT vs BBIO Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -25.76. In terms of profitability, CDT's ROE is +0.09%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, CDT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CDT vs KRTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CDT's ROE is +0.09%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CDT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CDT vs TECH Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 37.53. In terms of profitability, CDT's ROE is +0.09%, compared to TECH's ROE of +0.08%. Regarding short-term risk, CDT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TECH's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CDT vs HALO Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, HALO has a market cap of 11.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while HALO trades at $100.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 18.71. In terms of profitability, CDT's ROE is +0.09%, compared to HALO's ROE of +5.44%. Regarding short-term risk, CDT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for CDT.Check HALO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CDT vs SMMT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -12.63. In terms of profitability, CDT's ROE is +0.09%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, CDT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CDT vs RNAM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CDT's ROE is +0.09%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, CDT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CDT vs BMRN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 27.51. In terms of profitability, CDT's ROE is +0.09%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, CDT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CDT vs KYMR Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -35.24. In terms of profitability, CDT's ROE is +0.09%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, CDT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for CDT.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CDT vs PCVX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.31. In terms of profitability, CDT's ROE is +0.09%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, CDT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CDT vs MDGL Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -33.39. In terms of profitability, CDT's ROE is +0.09%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, CDT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CDT vs SYRE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -53.33. In terms of profitability, CDT's ROE is +0.09%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, CDT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CDT vs TGTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TGTX trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 23.37. In terms of profitability, CDT's ROE is +0.09%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, CDT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CDT vs RXDX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CDT's ROE is +0.09%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CDT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CDT vs PRAX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -25.38. In terms of profitability, CDT's ROE is +0.09%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, CDT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CDT vs NUVL Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CDT's ROE is +0.09%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CDT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for CDT.Check NUVL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CDT vs KRYS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while KRYS trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 38.25. In terms of profitability, CDT's ROE is +0.09%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, CDT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check KRYS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CDT vs CRNX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -16.86. In terms of profitability, CDT's ROE is +0.09%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CDT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CDT vs IMGN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CDT's ROE is +0.09%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CDT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CDT vs PTGX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 127.14. In terms of profitability, CDT's ROE is +0.09%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, CDT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CDT vs APGE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -31.19. In terms of profitability, CDT's ROE is +0.09%, compared to APGE's ROE of -0.30%. Regarding short-term risk, CDT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CDT vs BPMC Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CDT's ROE is +0.09%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CDT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CDT vs CERE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, CDT's ROE is +0.09%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CDT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CDT vs RYTM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -36.98. In terms of profitability, CDT's ROE is +0.09%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, CDT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CDT vs CYTK Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -7.77. In terms of profitability, CDT's ROE is +0.09%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, CDT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
CDT vs ABVX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -14.35. In terms of profitability, CDT's ROE is +0.09%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, CDT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CDT vs AXSM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -36.99. In terms of profitability, CDT's ROE is +0.09%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, CDT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
CDT vs MTSR Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CDT's ROE is +0.09%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, CDT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CDT vs TWST Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -50.27. In terms of profitability, CDT's ROE is +0.09%, compared to TWST's ROE of -0.23%. Regarding short-term risk, CDT is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CDT vs ORKA Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ORKA's P/E ratio is -54.30. In terms of profitability, CDT's ROE is +0.09%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, CDT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CDT vs IMVT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -12.12. In terms of profitability, CDT's ROE is +0.09%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, CDT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
CDT vs TXG Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TXG has a market cap of 7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -98.63. In terms of profitability, CDT's ROE is +0.09%, compared to TXG's ROE of -0.08%. Regarding short-term risk, CDT is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
CDT vs KOD Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, KOD has a market cap of 7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas KOD's P/E ratio is -26.66. In terms of profitability, CDT's ROE is +0.09%, compared to KOD's ROE of -2.88%. Regarding short-term risk, CDT is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for CDT.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
CDT vs MRUS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CDT's ROE is +0.09%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, CDT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CDT vs ARWR Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -21.24. In terms of profitability, CDT's ROE is +0.09%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, CDT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CDT vs ACLX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CDT's ROE is +0.09%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, CDT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
CDT vs CGON Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -27.66. In terms of profitability, CDT's ROE is +0.09%, compared to CGON's ROE of -0.25%. Regarding short-term risk, CDT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CDT vs BLTE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -87.89. In terms of profitability, CDT's ROE is +0.09%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, CDT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CDT vs CAI Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CAI's P/E ratio is 64.74. In terms of profitability, CDT's ROE is +0.09%, compared to CAI's ROE of +0.16%. Regarding short-term risk, CDT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CDT vs RETA Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, CDT's ROE is +0.09%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CDT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CDT vs IBRX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -6.21. In terms of profitability, CDT's ROE is +0.09%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, CDT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CDT vs CNTA Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CDT's ROE is +0.09%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CDT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CDT vs LGND Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 33.90. In terms of profitability, CDT's ROE is +0.09%, compared to LGND's ROE of +0.05%. Regarding short-term risk, CDT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for CDT.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CDT vs MIRM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -6.46. In terms of profitability, CDT's ROE is +0.09%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, CDT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CDT vs TERN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, CDT's ROE is +0.09%, compared to TERN's ROE of -0.14%. Regarding short-term risk, CDT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CDT vs CDTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CDT's ROE is +0.09%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, CDT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
CDT vs ABCM Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CDT's ROE is +0.09%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CDT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CDT vs ISEE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CDT's ROE is +0.09%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CDT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
CDT vs ERAS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -16.84. In terms of profitability, CDT's ROE is +0.09%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, CDT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
CDT vs MANE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -41.27. In terms of profitability, CDT's ROE is +0.09%, compared to MANE's ROE of -0.20%. Regarding short-term risk, CDT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CDT vs PTCT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -45.35. In terms of profitability, CDT's ROE is +0.09%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, CDT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CDT vs SRRK Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -12.52. In terms of profitability, CDT's ROE is +0.09%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, CDT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for CDT.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CDT vs APLS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, CDT's ROE is +0.09%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CDT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CDT vs DNTH Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -22.12. In terms of profitability, CDT's ROE is +0.09%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, CDT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for CDT.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CDT vs COGT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, COGT has a market cap of 5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -13.54. In terms of profitability, CDT's ROE is +0.09%, compared to COGT's ROE of -0.71%. Regarding short-term risk, CDT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CDT vs EWTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -24.83. In terms of profitability, CDT's ROE is +0.09%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, CDT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CDT vs TVTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -112.56. In terms of profitability, CDT's ROE is +0.09%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, CDT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CDT vs IONS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -8.89. In terms of profitability, CDT's ROE is +0.09%, compared to IONS's ROE of -1.20%. Regarding short-term risk, CDT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CDT vs ADPT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ADPT's P/E ratio is -70.83. In terms of profitability, CDT's ROE is +0.09%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, CDT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CDT vs FOLD Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CDT's ROE is +0.09%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, CDT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for CDT.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CDT vs AKRO Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CDT's ROE is +0.09%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, CDT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for CDT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CDT vs ALPN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CDT's ROE is +0.09%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CDT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CDT vs DFTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas DFTX's P/E ratio is N/A. In terms of profitability, CDT's ROE is +0.09%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, CDT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
CDT vs TNGX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TNGX's P/E ratio is -30.72. In terms of profitability, CDT's ROE is +0.09%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, CDT is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
CDT vs OPT Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, CDT's ROE is +0.09%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CDT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for CDT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CDT vs PRTC Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CDT's ROE is +0.09%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CDT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for CDT.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CDT vs MRTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CDT's ROE is +0.09%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CDT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CDT vs CRSP Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -8.87. In terms of profitability, CDT's ROE is +0.09%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, CDT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
CDT vs RLAY Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RLAY's P/E ratio is -11.52. In terms of profitability, CDT's ROE is +0.09%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, CDT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CDT vs XENE Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, XENE has a market cap of 4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -8.61. In terms of profitability, CDT's ROE is +0.09%, compared to XENE's ROE of -0.40%. Regarding short-term risk, CDT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for CDT.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
CDT vs TARS Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, TARS has a market cap of 4B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -73.65. In terms of profitability, CDT's ROE is +0.09%, compared to TARS's ROE of -2.46%. Regarding short-term risk, CDT is more volatile compared to TARS. This indicates higher risk in terms of short-term price fluctuations for CDT.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
CDT vs AMLX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas AMLX's P/E ratio is -20.19. In terms of profitability, CDT's ROE is +0.09%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, CDT is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
CDT vs CPRX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 17.49. In terms of profitability, CDT's ROE is +0.09%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CDT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
CDT vs ABCL Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ABCL's P/E ratio is -21.28. In terms of profitability, CDT's ROE is +0.09%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, CDT is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CDT vs RYZB Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CDT's ROE is +0.09%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CDT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for CDT.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CDT vs CBAY Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CDT's ROE is +0.09%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CDT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for CDT.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CDT vs VKTX Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -5.41. In terms of profitability, CDT's ROE is +0.09%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, CDT is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for CDT.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CDT vs ELVN Comparison November 2026
CDT Equity Inc. (NASDAQ: CDT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CDT stands at 181.9K. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, CDT is priced at $0.40 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CDT currently has a P/E ratio of N/A, whereas ELVN's P/E ratio is -29.22. In terms of profitability, CDT's ROE is +0.09%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, CDT is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for CDT.Check ELVN's competition here